On the afternoon of December 20th, Deputy Commissioner, Mr. He Hua met a delegation from GlaxoSmithKline Limited, led by President Mr. Paul R Carter of the China/Hongkong Quarter.

GlaxoSmithKline Global is headquartered in the UK, with its operations based in the US. GlaxoSmithKline (China) Investment Co. Ltd. has been established as one of the largest multinational pharmaceutical companies in China. Its subsidiary companies, SmithKline & French Labs Ltd. and Chongqing Glaxo are famous national wide for their products of high quality and reasonable price. GSK has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. 

During the meeting, Deputy Commissioner He briefed the GSK delegation on the recent patent examination affairs of SIPO. On the GSK side, President Carter mentioned the two patent applications submitted by his company, which were essential for his company's development. Mr. He replied that by adhering to principles of fair, equitable and timely, SIPO would examine their applications under the patent law. He also pointed out that suggestions on SIPO's patent examination affairs from any society, including GSK, are most welcomed.

As the GSK representatives raised a few other questions on their applications, the Deputy Director of the Chemistry Invention Examination Department, Mr. Chen Wei, and Deputy Division Director of the Department, Ms. Zhou Hubin, gave them detailed answers.

2005-01-09

2005-01-09